The use of nicotine replacement therapy in pregnancy has been debated but evidence suggests that it is safer than smoking. A cross-sectional survey was conducted with: (i) general practitioners and obstetricians from a college database; and (ii) general practitioners with a special interest in Indigenous health. General practitioners had higher odds of prescribing compared to obstetricians. Reading guidelines, confidence, viewing nicotine replacement therapy as safe, effective and with good adherence, also significantly increased the odds of prescription.
INTRODUCTION
Smoking in pregnancy is an important risk factor for adverse pregnancy and fetal outcomes. 1 The use of nicotine replacement therapy (NRT) during pregnancy has been debated due to the potential harmful effects of nicotine on fetal development.
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However, NRT provides a slower and lower absorption rate of nicotine, compared to smoking. 5 Due to the higher metabolism of nicotine in pregnancy, 6 pregnant women who smoke might need a higher NRT dose than non-pregnant women.
1,2,6
In the 2015 Cochrane review, NRT use during pregnancy increased cessation by 40% (relative risk 1.41, 95% CI 1.03-1.93), and was not associated with any harmful effects. 1 In UK stop smoking services, 7 combination NRT (oral NRT combined with a nicotine patch) was significantly associated with smoking cessation compared to pregnant women not receiving NRT (OR = 1.93, 95% CI 1.13-3.29), whereas using one form of NRT was not effective (odds ratio (OR) = 1.06, 95% CI 0.6-1.86)
The Royal Australian College of General Practitioners (RACGP) 8 guidelines recommend that pregnant women who are motivated to quit, and have been unsuccessful without medication, should be offered NRT after discussing the relative risks and benefits. The
Royal Australian and New Zealand College of Obstetricians and
Gynaecologists (RANZCOG) Statement 9 does not routinely recommend using NRT in pregnancy, yet acknowledges that NRT might be used with pregnant women who are highly dependent, and unable to quit.
International studies have found that NRT prescribing rates during pregnancy were relatively low, ranging 7-55%. 10-13 Safety concerns and lack of training were mentioned as common barriers.
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Using NRT during pregnancy is recommended to be under the supervision of a health professional. 8 Nonetheless, NRT can be bought Y. Bar-Zeev et al.
over the counter, and therefore for the purpose of this study, NRT prescription refers to either a prescription and/or a recommendation for NRT use.
This study aimed to examine: (i) self-reported NRT prescription rates during pregnancy; and (ii) the association between clinicianrelated factors, including attitudes, confidence and guidelines awareness, and NRT prescription rate, in Australian general practitioners (GPs) and obstetricians,
MATERIALS AND METHODS

Design
A national self-administered cross-sectional survey (July to November 2015).
Sample
Eligible participants were Australian obstetricians or GPs with or without obstetric training, who confirm pregnancy or consult with pregnant women.
Procedures
Two sampling methods were used: (i) a paper survey sent as an insert 
Survey
Included questions were about participants' characteristics, selfreported provision of smoking cessation care, including NRT prescription, factors associated with prescribing NRT in pregnancy, and a self-assessment of barriers and enablers to providing smoking cessation care. The full survey description can be found elsewhere. 14 Results presented here include self-reported prescription of NRT and factors related to prescribing NRT in pregnancy.
Participant characteristics
These included gender, years since medical qualification, smoking status, the population to which the medical practice mostly caters for (general or Aboriginal and Torres Strait Islander), and work location postcode (for rural, remote and urban classification).
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Frequency of prescribing NRT
A 5-point Likert scale was used: Never (0%); Occasional (1-25%);
Sometimes (26-50%); Often (51-75%); Always (76-100%). Another set of questions, with the same Likert scale, asked specifically the prescription rates of: (i) oral forms; (ii) patches; and (iii) combination NRT.
Clinician factors associated with prescribing NRT
Clinicians were asked to rate the following factors: perceived safety, effectiveness and women's adherence to NRT. Selfreported confidence (to prescribe) was measured using a 5-point
Likert scale (strongly disagree to strongly agree). Separate ordinal regressions were performed to examine the associations between each clinician factor listed above on NRT prescription frequency, adjusted for gender and years from medical qualification to account for possible confounding.
RESULTS
Sample characteristics
The survey was completed by 378 clinicians (42 RACGP GPs, 157 RANZCOG GPs and 178 obstetricians, one missing the answer regarding specialty; response rate 6.2%), from all Australian states and territories. Most GPs (81.4% (n = 162)) had obstetric training, 97.5% (n = 153) of RANZCOG GPs, and 21.4% (n = 9) of RACGP GPs.
A full description can be found elsewhere.
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Prescription of NRT and clinician factors associated with prescribing NRT
'Never' prescribing NRT was reported by 25.1% (n = 93), more so by obstetricians (38.9%, n = 68) compared to RACGP GPs (12.2%, n = 5, P < 0.001), and RANZCOG GPs (13%, n = 20, P < 0.001). Nearly half (49.9%, n = 181) reported 'never' prescribing combination NRT:
fewer RACGP GPs (30%, n = 12), compared to obstetricians (58.1%, n = 100, P < 0.001) and RANZCOG GPs (45.7%, n = 69, P = 0.004).
Clinician factors associated with NRT prescribing are presented in Table 1 . 
Associations between clinician factors and prescription of NRT
DISCUSSION
Main findings
Twenty-five percent of participants reported 'never' prescribing NRT during pregnancy. Nearly half (49.9%) reported they 'never' prescribe combination NRT. Being an obstetrician, low confidence and uncertainty over NRT safety, effectiveness and adherence, were all independently associated with lower odds of prescribing NRT.
Comparison with the literature
These findings are consistent with previous international studies showing low levels of NRT prescription and low levels of confidence, associated particularly with safety concerns. 11, 13, [16] [17] [18] [19] The low frequency of NRT prescription could partly be explained by the lack of a strong evidence base on the effectiveness and safety of NRT in pregnancy.
Women may hold negative views regarding NRT use during pregnancy. 20 A clinician's low confidence might be partially attributable to their perceived ability to potentially address negative patient views.
Reading the RACGP guidelines was associated with higher odds of prescribing. As these guidelines are more 'favourable' for NRT use in pregnancy, this highlights the need for clear practical up-to-date guidelines that can direct clinicians' decisions.
Implication for policy and practice
Further research is needed to strengthen the evidence base regarding NRT safety and effectiveness in pregnancy, specifically in regard to using higher doses and combination NRT. 1 Specific training on the management of smoking during pregnancy is essential, in particular on 'when' and 'how' to use NRT, 'how' to consult on the risks versus benefit of using NRT during pregnancy, and 'how' to proactively address patient concerns about using NRT. Guidelines need to be updated regularly, and be more practical. Pregnant women receive information from multiple health professionals as part of their prenatal care, and a consistent message is crucial for changing smoking behaviour.
A practical approach would be for clinicians to aid women to weigh up their relative risk versus benefit from using NRT in pregnancy. NRT provides lower levels of nicotine compared to smoking, and experts and guidelines agree that NRT is comparatively safer. This may assist in all pregnant women who smoke being offered an informed option about NRT treatment in a timely manner.
Limitations and strengths
Strengths of this study include national sampling, different geographical settings, and a subsample that was involved in 
CONCLUSIONS
NRT prescription rates during pregnancy are low: more so among obstetricians than GPs. Concerns over safety and low confidence are associated with lower odds of prescribing NRT. Training and practical detailed protocols may help change clinicians' views on the 'harm versus benefit' of NRT.
